ティッシュ ・ エンジニア リングの概要

Engineered tissue consists of three key components: a biomaterial scaffold that mimics the natural extracellular matrix, tissue-specific cells that define the tissue type, and growth factors that encourage tissue formation. The scaffold provides structure and promotes cell adhesion, while cells such as fibroblasts for skin or chondrocytes for cartilage give the tissue its functional identity.

Electrospinning applies voltage between a collection plate and a syringe tip containing biomaterial, creating micro-scale fibers that collect into a mat. The resulting scaffold must have interconnected micropores for cell and nutrient migration, adequate surface area for cell adhesion, and mechanical properties matching native tissue. This technique produces fiber mats suitable for various tissue types.

Three cell sources are available for tissue engineering: primary cells extracted from native tissue through enzymatic digestion, secondary cells from cell banks that are readily available but may cause rejection, and stem cells that are undifferentiated and can differentiate into specialized cell types or self-replicate. Each source has distinct advantages and limitations for clinical applications.

Natural tissues possess vascularization that delivers nutrients and removes waste, but engineered tissue relies on diffusion, which severely limits nutrient supply and restricts tissue size. This limitation prevents the creation of large, thick tissues needed for organ replacement. Researchers are developing synthetic scaffolds with built-in vasculature to address this critical challenge.

Tissue culture reactors mimic physiological conditions such as pulsatile flow found in arteries, providing mechanical stimulation that influences cell behavior and growth. Unlike static culture, these specialized systems promote development of endothelial and muscle cells by replicating the dynamic environment of natural tissue, leading to more functional engineered constructs.

Tissue engineering treats chronic wounds and burns using decellularized matrices with growth factors to promote cell migration, or cell-containing matrices that integrate into host tissue. Researchers also pursue organ replacement through organ culture, where donor organs are decellularized and recellularized with patient cells, reducing rejection risk and eliminating donor matching requirements.

Scaling tissue engineering for clinical use requires separate cell culture systems for each patient, involving time-intensive cell harvesting, expansion, and culturing on scaffolds. Regulatory challenges and high production costs further complicate broad implementation. These factors make it difficult to produce tissue in quantities sufficient for widespread clinical deployment.